Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GCN2iB is an ATP-competitive inhibitor of general control nonderepressible 2 (GCN2) with an IC50 of 2.4 nM.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 18,000 | |||
5 mg | 在庫あり | ¥ 41,000 | |||
10 mg | 在庫あり | ¥ 66,000 | |||
25 mg | 在庫あり | ¥ 132,500 | |||
50 mg | 在庫あり | ¥ 189,500 | |||
100 mg | 在庫あり | ¥ 259,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 45,000 |
説明 | GCN2iB is an ATP-competitive inhibitor of general control nonderepressible 2 (GCN2) with an IC50 of 2.4 nM. |
ターゲット&IC50 | GCN2:2.4 nM |
In vitro | GCN2iB shows an IC50 value of 2.4 nM for GCN2 and potent cellular activity. In a panel of 468 kinases, only GCN2 shows >99.5% inhibition, and three kinases (MAP2K5, STK10, and ZAK) show >95%inhibition at 1 μM GCN2iB, demonstrating high kinase selectivity. |
In vivo | In the antitumor activity study of the CCRF-CEM xenografts, ASNase or GCN2iB alone does not significantly affect tumor growth.Notably, a combination of ASNase and GCN2iB elicits potent antitumor activity (P=0.0002) with synergistic effects.In MV-4-11 and SU.86.86 xenografts, the robust antitumor activity of the combination of GCN2iB and ASNase is observed with a synergistic effect, respectively.ASNase/GCN2iB-treated tumors do not show significant growth even after drug cessation. |
分子量 | 451.83 |
分子式 | C18H12ClF2N5O3S |
CAS No. | 2183470-12-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/mL (121.73 mM), Sonication is recommended.
H2O: < 0.1 mg/mL (insoluble)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
GCN2iB 2183470-12-2 Autophagy Others inhibit GCN-2iB Inhibitor Eukaryotic Initiation Factor (eIF) inhibitor